查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1918083

關節疼痛注射劑市場－2026-2031年預測

Joint Pain Injections Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計關節疼痛注射市場將從 2025 年的 61.11 億美元成長到 2031 年的 93.64 億美元，複合年成長率為 7.37%。

關節疼痛注射市場呈現顯著上升趨勢，主要促進因素是全球骨關節炎和關節炎等肌肉骨骼疾病發生率的不斷上升。這些疾病嚴重影響患者的活動能力和生活品質，因此對有效的疼痛管理方案的需求很大。全球人口老化是加劇此需求的重要人口因素。關節疼痛注射（關節內注射）是一種微創手術，可將藥物直接輸送到關節內，以緩解疼痛和發炎。與全身性口服藥物和手術相比，關節疼痛注射具有恢復時間短、療效持久等優勢，已成為現代整形外科治療和慢性疼痛管理的基礎。

關鍵市場促進因素與限制因素

市場擴張的主要促進因素是全球關節疾病風險因子的增加。肥胖症的日益普及給關節帶來過大的機械負荷，增加了功能障礙和退化性疾病的風險。此外，久坐的生活方式會導致支撐肌肉力量減弱，進一步加劇關節脆弱性。人口結構轉變為老化也是一個根本性的促進因素，因為老齡化是骨關節炎發生的主要風險因素。

一個值得關注的市場趨勢是再生醫學的日益普及。傳統的注射療法，例如皮質類固醇和透明質酸，透過減輕發炎和補充關節液來緩解症狀，而富血小板血漿（PRP）和幹細胞療法等再生療法則旨在修復組織並促進關節的長期健康。越來越多的臨床證據支持其療效，患者對非手術治療方案的需求，以及細胞治療方法生產技術的進步，共同推動這些先進治療方法走向主流。

然而，市場成長也面臨一些限制因素。高昂的治療費用，尤其是再生醫學和需要多次注射的療程，可能會限制病患的就醫途徑。這項挑戰源自於保險覆蓋範圍有限或參差不齊，往往導致患者需要承擔高額的自付費用。此外，還有許多替代治療方法，包括物理療法、口服止痛藥、非類固醇消炎劑（NSAIDs）和輔助器具，它們與注射療法有競爭關係，尤其是在治療輕度至中度關節疼痛方面。

市場區隔與區域展望

市場按產品和關節類型細分。依產品分類，玻尿酸注射佔較大的市場佔有率，因其能有效緩解骨關節炎疼痛並改善活動能力而聞名。按關節類型分類，膝關節細分市場佔據最大的市場佔有率，這主要歸因於膝骨關節炎的高發病率以及膝關節承受的巨大壓力。

從區域來看，北美市場佔據主導地位。其主導地位得益於慢性關節疾病的高發生率、完善的醫療保健基礎設施以及創新治療方法的快速普及。歐洲也是一個成熟的市場，其特點是強大的製藥業和持續的醫療進步。

亞太地區預計將成為成長最快的地區，這主要得益於龐大且老化的人口、不斷提高的健康意識、不斷擴建的醫院基礎設施以及對醫藥研發投入的增加。南美洲和中東及非洲市場正在發展，成長主要集中在較富裕的都市區。醫療保健投資的增加、醫療旅遊的興起以及患者健康意識的提高正在推動這些地區的擴張，但由於基礎設施和成本的限制，遍遠地區的醫療服務仍然有限。

競爭格局與策略趨勢

市場競爭激烈，由跨國製藥和生技公司主導。主要企業正積極推行策略舉措以鞏固其市場地位。這些措施包括：大力開展以創新治療方法為重點的研發項目；建立策略聯盟和夥伴關係，以增強產品系列和分銷網路；以及拓展地域，將創新產品推向新市場。持續專注於創新，尤其是在再生醫學和先進治療解決方案領域，是塑造競爭格​​局的關鍵因素。

本報告的主要優勢：

  • 深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
  • 市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
  • 可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
  • 受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及影響、新產品開發、競爭影響

分析範圍

  • 歷史資料（2021-2025 年）和預測資料（2026-2031 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭對手定位、策略和市場佔有率分析
  • 按業務板塊和地區（國家）分類的收入成長和預測分析
  • 公司概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 分析範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策和法規
  • 策略建議

第4章 技術展望

第5章 關節疼痛注射市場（按類型分類）

  • 介紹
  • 皮質類固醇
  • 玻尿酸注射
  • 富血小板血漿（PRP）注射
  • 其他

第6章 依關節類型分類的關節疼痛注射市場

  • 介紹
  • 膝關節
  • 手腕關節
  • 髖關節
  • 其他

第7章 依最終使用者分類的關節疼痛注射劑市場

  • 介紹
  • 醫院
  • 診所
  • 其他

第8章 各地區關節疼痛注射市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Sanofi
  • Seikagaku Corporation
  • Bioventus
  • Anika Therapeutics, Inc.
  • Pacira BioSciences, Inc.
  • Dr. Reddy's Laboratories Ltd
  • Zimmer Biomet
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd.
  • Ferring Pharmaceuticals
  • Eli Lilly And Company

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061615514

Joint Pain Injections Market is expected to grow at a 7.37% CAGR, achieving USD 9.364 billion in 2031 from USD 6.111 billion in 2025.

The joint pain injections market is experiencing a significant uptrend, primarily driven by the rising global incidence of musculoskeletal conditions such as osteoarthritis and arthritis. These conditions profoundly impact patient mobility and quality of life, creating a substantial demand for effective pain management solutions. The growing elderly population worldwide is a key demographic factor amplifying this need. Joint pain injections, or intra-articular injections, represent a minimally invasive procedure where medication is administered directly into the joint to relieve pain and inflammation. Their appeal lies in offering faster recovery times and longer-lasting effects compared to systemic oral medications or surgical interventions, making them a cornerstone of modern orthopedic care and chronic pain management.

Primary Market Growth Drivers and Restraints

A major driver for market expansion is the global increase in risk factors for joint disease. The rising prevalence of obesity places excessive mechanical strain on joints, elevating the risk of dysfunction and degenerative conditions. Coupled with this, sedentary lifestyles can lead to weakened supporting musculature, further contributing to joint vulnerability. The demographic shift towards an older population is another fundamental driver, as age is a primary risk factor for the development of osteoarthritis.

A defining trend within the market is the rising adoption of regenerative therapies. While traditional injections like corticosteroids and hyaluronic acid provide symptomatic relief by reducing inflammation and supplementing joint fluid, regenerative options such as platelet-rich plasma (PRP) and stem cell therapies aim to promote tissue repair and long-term joint health. Growing clinical evidence supporting their efficacy, patient demand for alternatives to surgery, and technological advancements in cell therapy production are collectively propelling these sophisticated options into the mainstream.

However, the market's growth is tempered by certain restraints. The high cost of treatment, particularly for regenerative therapies and courses requiring multiple injections, can limit patient access. This challenge is often compounded by limited or variable insurance coverage, resulting in significant out-of-pocket expenses. Furthermore, a range of alternative treatments exists, including physical therapy, oral analgesics, NSAIDs, and assistive devices, which compete with injections, especially for managing mild to moderate joint pain.

Market Segmentation and Regional Outlook

The market is segmented by product and joint type. In terms of products, hyaluronic acid injections have secured a significant market share, valued for their ability to alleviate pain and improve mobility in osteoarthritic joints. Regarding joint type, the knee segment represents the largest market share, attributable to the high prevalence of knee osteoarthritis and the considerable stress the knee joint endures.

Geographically, North America holds a leading position in the market. This dominance is supported by a high prevalence of chronic joint diseases, a well-developed healthcare infrastructure, and a rapid rate of adoption for innovative therapies. Europe also represents a mature market, characterized by a strong pharmaceutical sector and continuous medical advancements.

The Asia-Pacific region is anticipated to witness the most rapid growth. This is fueled by a large and aging population, increasing healthcare awareness, expanding hospital infrastructure, and growing investments in pharmaceutical research and development. Markets in South America and the Middle East & Africa are developing, with growth concentrated in more affluent, urban areas. In these regions, expansion is driven by rising healthcare investment, growing medical tourism, and increasing patient awareness, though access remains limited in rural areas due to infrastructure and cost constraints.

Competitive Landscape and Strategic Developments

The market is competitively served by a mix of multinational pharmaceutical and biotechnology companies. Key players are actively engaged in strategic initiatives to strengthen their market position. These strategies include robust research and development programs focused on novel therapies, strategic collaborations and partnerships to enhance product portfolios and distribution, and geographic expansion efforts to commercialize innovative products in new markets. The competitive dynamics are shaped by a continuous focus on innovation, particularly in the realm of regenerative medicine and advanced therapeutic solutions.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Joint Pain Injections Market Segmentation:

  • By Type
  • Corticosteroid
  • Hyaluronic Acid Injections
  • Platelet Rich Plasma (PRP) Injections
  • Others
  • By Joint Type
  • Knee Joint
  • Hands & Wrist Joint
  • Hip Joint
  • Others
  • By End-User
  • Hospitals
  • Clinics
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. JOINT PAIN INJECTIONS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Corticosteroid
  • 5.3. Hyaluronic Acid Injections
  • 5.4. Platelet Rich Plasma (PRP) Injections
  • 5.5. Others

6. JOINT PAIN INJECTIONS MARKET BY JOINT TYPE

  • 6.1. Introduction
  • 6.2. Knee Joint
  • 6.3. Hands & Wrist Joint
  • 6.4. Hip Joint
  • 6.5. Others

7. JOINT PAIN INJECTIONS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Others

8. JOINT PAIN INJECTIONS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Italy
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Sanofi
  • 10.2. Seikagaku Corporation
  • 10.3. Bioventus
  • 10.4. Anika Therapeutics, Inc.
  • 10.5. Pacira BioSciences, Inc.
  • 10.6. Dr. Reddy's Laboratories Ltd
  • 10.7. Zimmer Biomet
  • 10.8. Pfizer Inc
  • 10.9. Teva Pharmaceutical Industries Ltd.
  • 10.10. Ferring Pharmaceuticals
  • 10.11. Eli Lilly And Company

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations